Mandy Moore's Fight Against RSV: Protecting Her Newborn from a Deadly Virus

Respiratory syncytial virus, or RSV, poses a serious threat to young children worldwide. Each year, it leads to millions of hospitalisations and thousands of deaths in infants under five. Now, parents like singer Mandy Moore are taking steps to shield their children from the virus.

RSV spreads rapidly during colder months, with the U.S. season typically running from October to March. Peaks often occur in December and January. The virus can cause severe breathing difficulties in infants, sometimes leading to retractions—where the chest sinks in with each breath—and even respiratory failure.

Without protection, around 40% of infected babies develop lower respiratory infections that may require hospital care. Globally, the World Health Organization reports about 3.6 million hospitalisations and 100,000 deaths annually among young children due to RSV.

To combat this, two main prevention methods exist. Pregnant women can receive an RSV vaccine, passing antibodies to their unborn child. Alternatively, infants can be given monoclonal antibodies like nirsevimab (Beyfortus) or clesrovimab (Enflonsia).

Mandy Moore experienced the virus firsthand when her two sons, August and Oscar, fell ill in 2023. Though their cases were mild, the ordeal left her and her husband deeply concerned. Determined to protect her newborn daughter, Louise, Moore opted for Beyfortus, a monoclonal antibody treatment.

RSV remains a major health risk for young children, but preventive measures are available. Vaccines for pregnant mothers and monoclonal antibodies for infants offer ways to reduce severe illness. Moore's decision reflects a growing trend of parents seeking protection for their most vulnerable family members.